Follow
Marina Chiara Garassino
Marina Chiara Garassino
Verified email at medicine.bsd.uchicago.edu
Title
Cited by
Cited by
Year
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
87342015
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ...
New England journal of medicine 378 (22), 2078-2092, 2018
54812018
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ...
New England Journal of Medicine 376 (7), 629-640, 2017
33152017
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
14902019
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer
S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ...
Journal of clinical oncology 38 (14), 1505-1517, 2020
8822020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
6412020
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ...
New England Journal of Medicine 383 (10), 931-943, 2020
6282020
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
MC Garassino, O Martelli, M Broggini, G Farina, S Veronese, E Rulli, ...
The lancet oncology 14 (10), 981-988, 2013
5792013
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ...
Journal of Clinical Oncology 40 (12), 1301, 2022
5612022
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
5332018
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ...
Annals of oncology 29 (4), 959-965, 2018
4552018
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet Oncology 22 (1), 51-65, 2021
4132021
CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3)
YL Wu, MJ Ahn, MC Garassino, JY Han, N Katakami, HR Kim, R Hodge, ...
Journal of Clinical Oncology 36 (26), 2702-2709, 2018
4112018
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
F Barlesi, J Vansteenkiste, D Spigel, H Ishii, M Garassino, F de Marinis, ...
The Lancet Oncology 19 (11), 1468-1479, 2018
4022018
Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer
H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, ...
Journal of Clinical Oncology 39 (7), 723, 2021
4012021
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)
SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, ...
Journal of Clinical Oncology 39 (6), 619, 2021
4012021
Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1–selected advanced non–small-cell lung cancer (BIRCH)
S Peters, S Gettinger, ML Johnson, PA Jänne, MC Garassino, D Christoph, ...
Journal of Clinical Oncology 35 (24), 2781, 2017
4002017
Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial
C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, ...
Journal of Thoracic Oncology 16 (5), 860-867, 2021
3872021
Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade
G Lo Russo, M Moro, M Sommariva, V Cancila, M Boeri, G Centonze, ...
Clinical Cancer Research 25 (3), 989-999, 2019
3842019
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ...
Annals of Oncology 32 (7), 881-895, 2021
3122021
The system can't perform the operation now. Try again later.
Articles 1–20